The effects of empagliflozin in patients with type 1 diabetes: Results of a 12-week, double-blind, randomized, placebo-controlled clinical trial

The effects of empagliflozin in patients with type 1 diabetes: Results of a 12-week, double-blind, randomized, placebo-controlled clinical trial

Background: Sodium-glucose cotransporter-2 (SGLT-2) acts as a key element in the reabsorption of glucose in the kidney. Currently, SGLT-2 inhibitors are FDA-approved for the treatment of type 2 diabetes. It is suggested that the mechanism of action may operate in the treatment of type 1 diabetes mel...

Full description

Saved in:
Bibliographic Details
Main Authors: Mostafa Najafipour, Farzad Najafipour, Alireza Ostadrahimi, Maryam Ghavami, Zohreh Razaghi, Helda Tutunchi, Naimeh Mesri Alamdari
Format: Article
Language:English
Published: Tabriz University of Medical Sciences 2024-12-01
Series:Health Promotion Perspectives
Subjects:
empagliflozin
sodium-glucose transporter 2 inhibitors
type 1 diabetes
Online Access:https://hpp.tbzmed.ac.ir/PDF/hpp-14-380.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items